Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases

M. Tadolini; L. Codecasa; J. García-García; F. Blanc; S. Borisov; J. Alffenaar; C. Andréjak; P. Bachez; P. Bart; E. Belilovski; J. Cardoso-Landivar; R. Centis; L. D’Ambrosio; S. De; A. Dominguez-Castellano; S. Dourmane; M. Jachym; A. Froissart; V. Giacomet; D. Goletti; S. Grard; G. Gualano; A. Izadifar; D. Le; M. Royo; J. Mazza-Stalder; I. Motta; O. Min; F. Palmieri; F. Rivière; T. Rodrigo; D. Silva; A. Sánchez-Montalvá; M. Saporiti; P. Scarpellini; F. Schlemmer; A. Spanevello; E. Sumarokova; E. Tabernero; P. Tambyah; S. Tiberi; A. Torre; D. Visca; M. Murguiondo; G. Sotgiu; G. Migliori

Статья

Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases

M. Tadolini, L. Codecasa, J. García-García, F. Blanc, S. Borisov, J. Alffenaar, C. Andréjak, P. Bachez, P. Bart, E. Belilovski, J. Cardoso-Landivar, R. Centis, L. D’Ambrosio, S. De, A. Dominguez-Castellano, S. Dourmane, M. Jachym, A. Froissart, V. Giacomet, D. Goletti, S. Grard, G. Gualano, A. Izadifar, D. Le, M. Royo, J. Mazza-Stalder, I. Motta, O. Min, F. Palmieri, F. Rivière, T. Rodrigo, D. Silva, A. Sánchez-Montalvá, M. Saporiti, P. Scarpellini, F. Schlemmer, A. Spanevello, E. Sumarokova, E. Tabernero, P. Tambyah, S. Tiberi, A. Torre, D. Visca, M. Murguiondo, G. Sotgiu, G. Migliori,

2021

https://doi.org/10.1183/13993003.01398-2020

Цитирование

Источник

Версии

1. Version of Record от 2021-04-27

Метаданные

Об авторах

M. Tadolini
Unit of Infectious Diseases, Dept of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy
L. Codecasa
TB Reference Centre, Villa Marelli Institute, Niguarda Hospital, Milan, Italy
J. García-García
Tuberculosis Research Programme (PII-TB), SEPAR, Barcelona, Spain
F. Blanc
Centre Hospitalier Universitaire, Nantes, France
S. Borisov
Moscow Research and Clinical Center for TB Control, Moscow, Russian Federation
J. Alffenaar
University of Sydney, Sydney Pharmacy School, Sydney, Australia
C. Andréjak
Westmead Hospital, Sydney, Australia
P. Bachez
Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, Australia
P. Bart
Service de Pneumologie CHU AMIENS PICARDIE, France and UR Université de Picardie Jules Verne, Amiens, France
E. Belilovski
Service de Pneumologie, Clinique Saint Luc, Bouge, Belgium
J. Cardoso-Landivar
Dept of Internal Medicine, Lausanne University, Lausanne, Switzerland
R. Centis
Servicio Neumología, Vall D´Hebron University Hospital, Barcelona, Spain
L. D’Ambrosio
Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
S. De
Public Health Consulting Group, Lugano, Switzerland
A. Dominguez-Castellano
Servicio de Enfermedades Infecciosas y Microbiología, Hospital Virgen Macarena, Sevilla, Spain
S. Dourmane
Service de Pneumologie, Groupe hospitalier sud île de France (GHSIF), Melun, France
M. Jachym
Centre Hospitalier de Bligny, Briis Sous Forges, France
A. Froissart
Service de Médecine interne, CHI de Créteil, Créteil, France
V. Giacomet
Pediatric Infectious Diseases Unit, Dept of Biomedical and Clinical Sciences, L. Sacco Hospital, University of Milan, Milan, Italy
D. Goletti
Translational Research Unit, National Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy
S. Grard
Centre de Lutte Antituberculeuse (CLAT 38), Grenoble, France
G. Gualano
Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases ‘L. Spallanzani’, IRCCS, Rome, Italy
A. Izadifar
Hôpital Européen de Paris La Roseraie, Aubervilliers, France
D. Le
Servicio Neumología, Hospital General Universitario de Castellón, Castelló, Spain
M. Royo
Pulmonary Division, Lausanne University Hospital CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J. Mazza-Stalder
Dipartimento di Scienze Mediche, Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy
I. Motta
Dept of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
O. Min
Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore, Singapore
F. Palmieri
Hôpital d’Instruction des Armées (HIA) Percy, Clamart, France
F. Rivière
Faculdade de Medicina, Universidade Federal do Rio Grande do Sul – UFRGS, Porto Alegre, Brazil
T. Rodrigo
Infectious Diseases Dept, International Health and Tuberculosis Unit, Vall d’Hebron University Hospital, Barcelona, Spain
D. Silva
Vall d’Hebron Institute of Research (VHIR), Barcelona, Spain
A. Sánchez-Montalvá
Grupo de Estudio de Infecciones por Micobacterias (GEIM), Spanish Society of Infectious Diseases (SEIMC), Spain
M. Saporiti
Unit of Infectious Diseases, Università Vita e Salute, San Raffaele Hospital, Milan, Italy
P. Scarpellini
Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, France
F. Schlemmer
Division of Pulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, Tradate, Italy
A. Spanevello
Dept of Medicine and Surgery, Respiratory Diseases, University of Insubria, Tradate, Italy
E. Sumarokova
Servicio Neumología, Hospital de Cruces, Bilbao, Spain
E. Tabernero
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
P. Tambyah
Division of Infection, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom
S. Tiberi
Dept of Infectious Diseases, University of Milan, L. Sacco Hospital, Milan, Italy
A. Torre
Servicio Neumología Hospital Universitario Marqués de Valdecilla, Santander, Spain
D. Visca
Clinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
M. Murguiondo
G. Sotgiu
G. Migliori

Название журнала

European Respiratory Journal

Том

Выпуск

Страницы

Ключевые слова

acetylcysteine; azithromycin; BCG vaccine; cobicistat plus darunavir; enoxaparin; hydroxychloroquine; lopinavir plus ritonavir; tuberculostatic agent; antivirus agent; azithromycin; hydroxychloroquine; lopinavir; lopinavir-ritonavir drug combination; ritonavir; adult; aged; alcohol abuse; asthma; Belgium; Brazil; case fatality rate; chronic obstructive lung disease; clinical article; clinical evaluation; cohort analysis; comorbidity; coronavirus disease 2019; drug abuse; extrapulmonary tuberculosis; female; France; high resolution computer tomography; human; Human immunodeficiency virus infection; Italy; kidney failure; Letter; liver disease; lung tuberculosis; male; medical history; migrant; mixed infection; Mycobacterium tuberculosis; nucleic acid analysis; physician; priority journal; radiological technologist; Russian Federation; Severe acute respiratory syndrome coronavirus 2; Singapore; smoking; Spain; sputum culture; Switzerland; thorax radiography; treatment outcome; tuberculosis; unemployment; virus pneumonia; Betacoronavirus; complication; Coronavirus infection; diagnostic imaging; drug combination; laboratory technique; lung; lung tuberculosis; middle aged; mixed infection; mortality; pandemic; tuberculosis; virus pneumonia; x-ray computed tomography; Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Cohort Studies; Coinfection; Coronavirus Infections; Drug Combinations; Emigrants and Immigrants; Female; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Middle Aged; Mortality; Pandemics; Pneumonia, Viral; Ritonavir; Tomography, X-Ray Computed; Tuberculosis; Tuberculosis, Pulmonary

Издатель

European Respiratory Society

Тип документа

Letter

Тип лицензии Creative Commons

Правовой статус документа

Свободная лицензия

Источник

scopus

Поиск по репозиторию

Статья

Active tuberculosis, sequelae and COVID-19 co-infection: First cohort of 49 cases

Похожие публикации

Источник

Версии

Метаданные